BridgeMD
New treatment option for Aphasia
Official title Neuroplasticity Biomarkers in Aphasia
ClinicalTrials.gov ID: NCT06471127
What this study is testing
- What it's testing
- Patients with stroke frequently suffer from aphasia, a disorder of expressive and/or receptive language, that can lead to serious health consequences, including social isolation, depression, reduced quality of life, and increased caregiver burden. Aphasia recovery varies greatly between individuals, and likely relies upon the capacity for neuroplasticity, both at a systems level of reorganized brain networks and a molecular level of neuronal repair and plasticity.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 40 to 90
You may be able to join if
- Ages 40-90
- Right-handed (prior to stroke)
- Proficient English speakers
- History of a single ischemic stroke in the middle cerebral artery territory that is lateralized to the left or right (Aim 1) cerebral hemisphere.
- Presence of aphasia (Aims 2-3)
You likely can't join if
- History of significant medical or neurological disorder (other than stroke)
- History of significant or poorly controlled psychiatric disorders
- Current abuse of alcohol or drugs, prescription or otherwise
- Clinically significant and uncorrected vision or hearing loss
- Anything other than standard of care stroke treatment such as Plavix, aspirin (81-300 mg daily), beta-blockers, diabetes medications or choles-...
See the full eligibility criteria
- Ages 40-90
- Right-handed (prior to stroke)
- Proficient English speakers
- History of a single ischemic stroke in the middle cerebral artery territory that is lateralized to the left or right (Aim 1) cerebral hemisphere.
- Presence of aphasia (Aims 2-3)
- Capacity to understand the nature of the study and provide informed consent
- Acute or subacute stroke at the time of Aim 1 enrollment; Stroke #12 months old (chronic) at the time of Aims 2-3 enrollment
- Medically stable
- History of significant medical or neurological disorder (other than stroke)
- History of significant or poorly controlled psychiatric disorders
- Current abuse of alcohol or drugs, prescription or otherwise
- Clinically significant and uncorrected vision or hearing loss
- Anything other than standard of care stroke treatment such as Plavix, aspirin (81-300 mg daily), beta-blockers, diabetes medications or choles- terol-lowering agents, thrombolytics (e.g., tPA), anticoagulation agents...
The study team makes the final eligibility decision.
Where it's taking place
- Madison, Wisconsin, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 40 years to 90 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Madison, Wisconsin, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.